MarketPulse

cell and gene therapy

5 articles
BenzingaBenzinga··Prnewswire

Cryoport Accelerates Growth With 16% Q1 Revenue Surge, Raises 2026 Guidance

Cryoport reports Q1 2026 revenue of $47.8M, up 16% YoY, raising full-year guidance to $192-196M as CGT revenue surges.
CYRXclinical trialsrevenue growth
BenzingaBenzinga··Prnewswire

BioLife Solutions to Unveil Q1 2026 Results as Biopreservation Leader Eyes Growth

BioLife Solutions will report Q1 2026 earnings May 7, 2026, with management providing financial results and business updates via conference call.
BLFSearnings announcementconference call
BenzingaBenzinga··Prnewswire

BioLife Solutions Wins INTERPHEX Award for CryoCase Innovation in Gene Therapy

BioLife Solutions wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase, addressing container failures in cell and gene therapy manufacturing.
BLFScell and gene therapybiotech innovation
BenzingaBenzinga··Prnewswire

BioLife Solutions Posts 29% Revenue Growth in 2025, Eyes Continued Expansion

BioLife Solutions achieved 29% revenue growth in 2025, reaching $96.2 million. The company expects 17-20% growth in 2026 and projects full-year profitability.
BLFSclinical trialsrevenue growth
BenzingaBenzinga··Prnewswire

BioLife Solutions to Unveil 2025 Results and Strategic Update Feb. 26

BioLife Solutions will release 2025 financial results and host a conference call on February 26, 2026, discussing earnings and strategic updates for its cell therapy preservation business.
BLFSfinancial resultsearnings announcement